Action against opioid misuse gaining traction, report finds

10 May 2019
addiction_pills_syringe_big

A new report from industry analyst IQVIA Institute for Human Data Scienc has found that opioid prescriptions in the USA have declined 17% in the last year, the largest annual drop ever.

The researchers found that while the volume of opioid prescriptions increased every year since 1992, a series of regulatory and legislative measures enacted in 2011 caused a 4% year-on-year decline, followed by a 12% decline in 2017 and a 17% drop in 2018.

In recent years, the USA has been in the grip of an opioid crisis, with  pharmaceutical marketing practices blamed for widespread overprescribing and subsequent opioid misuse.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical